Read-Gene S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2005-09-27
Share capital
589,500.50 PLN
Activity description

Read-Gene develops and commercializes genetic tests and offers services involving microelements and diet modifications. Its work also includes methods for detecting, preventing and treating malignant tumors, with DNA tests intended to support prevention and earlier treatment for people with genetic cancer predispositions. The company collaborates with medical professionals from the International Center for Hereditary Cancers at the Pomeranian Medical University in Szczecin.

Registered address
Akacjowa 2, 71-253 Szczecin, Poland
Branches
  • ul. Alabastrowa 8, 72-003 Dobra
  • ul. Choroszczańska 24, 15-732 Białystok
  • ul. Tadeusza Rejtana 1, 85-032 Bydgoszcz
  • ul. Broniewskiego 9, 85-316 Bydgoszcz
  • ul. Limanowska 22A, 33-395 Chełmiec
Email
Phone
Social media

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$4,626

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 9 days for 2022). All were audited by a statutory auditor.

  • 202501/07/2026
  • 202414/07/2025
  • 202319/07/2024
  • 202224/07/2023
  • 202113/07/2022
  • 202003/08/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 4.80
0.00 (0.00%)
4.504.604.704.804.8010:0012:0014:0016:00
Open
PLN 4.74
High
PLN 4.80
Low
PLN 4.50
Volume
760
Avg. vol.
195
Market cap
PLN 56.59M
P/E ratio
25.26
EPS
PLN 0.19
Shares outstanding
11.79M
52-week
PLN 4.50 – 4.88
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
NewConnect

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 901.67kUSD -80.23kUSD -79.96k
Q2 2026USD 1.13mUSD -116.96kUSD 113.45k
Q1 2026USD 1.05mUSD 203.94kUSD 199.08k
Q4 2025USD 1.29mUSD 193.12kUSD 108.74k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 9.7%
City · Szczecin759 / 4,608
Top 16%
Voivodeship · Zachodniopomorskie1,948 / 10,443
Top 19%
Country · Poland58,011 / 297,069
Top 20%

Results vs industry

Revenue
This companyUSD 2.16mMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 162.14kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 1.86mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 3.38mMedianUSD 134.71kAverageUSD 3.04m

Offer

Websites

The site is available in: Polish and English. The site targets these markets: United States.

  • read-gene.comStrona główna – Read-Gene S.A.
    WordPress 7.1ElementorGoogle AnalyticsGoogle Tag ManagerYoast SEOApache

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. 6 marks have expired or were not registered. The first mark was filed in 2010.

MarkNumberClassesStatusProtected until
CYNK-GEN (word)Z.5516345Protected Oct 18, 2032
ONKOPAKIET READ-GENE (word)Z.5809205, 42, 44Refused –
ONKOPIERWIASTKI READ-GENE (word)Z.5809215, 42, 44Refused –
ONKOPAKIET (word)Z.5809195, 42, 44Refused –
Fer-Nat (word)Z.4012585Expired –
MarkProtected until
CYNK-GEN (word)Oct 18, 2032
ONKOPAKIET READ-GENE (word)–
ONKOPIERWIASTKI READ-GENE (word)–
ONKOPAKIET (word)–
Fer-Nat (word)–

Authorized Representatives

Jan Antoni Lubiński age 73 – President of the Management Board
Karolina Ertmańska age 51 – Attorney-in-fact
Wojciech Marciniak age 36 – Attorney-in-fact (sole)

Manner of representation

The following persons are authorized to submit declarations of will on behalf of the company: in the case of a one-person management board – the President of the Management Board or each of the commercial proxies independently, and in the case of a multi-member management board – the President of the Management Board independently, or one member of the management board jointly with a commercial proxy.

Supervisory board

Adam Szuba age 54 – Supervisory Board Member
Sebastian Bryła age 50 – Supervisory Board Member
Tadeusz Dębniak age 55 – Supervisory Board Member
Jacek Gronwald age 61 – Supervisory Board Member
Marcin Lener age 50 – Supervisory Board Member

Beneficial owners

Person

Subsidiaries

NameStake
100%

Bank accounts

Registered as a VAT taxpayer on 2010-09-30.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$148.8K
Buildings and premises
$1.1M

Public aid

4 public aid cases recorded, with a total value of $40,999.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$24,952
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,309
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$5,426

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Histamed Dc sp. z o.o.
Akademicki Ośrodek Diagnostyki Patomorfologicznej I Genetyczno-Molekularnej sp. z o.o.
Testdna sp. z o.o.
Genos sp. z o.o.
Imedlab sp. z o.o.
Info-Pat sp. z o.o. sp. k.
Warsaw Genomics sp. z o.o.
Laboratorium Analityczne sp. z o.o.
Diagen Diagnostyka Genetyczna dla Rodziny sp. z o.o.
Inngen Laboratorium Badań Genetycznych sp. z o.o.

Change history

DateEvent
2020-09-03Switch to PKD 2007
2009-06-19Share capital reduction
2009-01-16Share capital increase
2005-09-27Entered in the register

FAQ

Last updated: 2026-08-20